Phase IIb Protocol 011 Safety Analysis at Week 96: Islatravir Plus Doravirine Following Islatravir, Doravirine, Lamivudine Induction

July 18-21, 2021; Virtual
After 24 weeks of 3-drug induction therapy in treatment-naive patients, islatravir plus doravirine dual therapy was generally well tolerated through 96 weeks.
Format: Microsoft PowerPoint (.ppt)
File Size: 258 KB
Released: July 20, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism

person default Yvette Raphael Released: June 21, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Gregory Huhn, MD, MPHTM Daniel R. Kuritzkes, MD Babafemi Taiwo, MBBS
Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: June 17, 2022 Expired: June 16, 2023

Clinical Care Options (CCO) downloadable slides from Yvonne Gilleece providing an overview of investigational long-acting HIV care and prevention approaches

Babafemi Taiwo, MBBS
Program Director
person default Yvonne Gilleece, MB BCh, BAO
Released: June 14, 2022

Expert selections of cutting-edge HIV data, including the latest on long-acting therapies and pre-exposure prophylaxis

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: May 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings